Piotr JÃ³zef Rudzki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4608600/publications.pdf Version: 2024-02-01

		840776	752698
32	414	11	20
papers	citations	h-index	g-index
33	33	33	539
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?. Journal of Pharmaceutical and Biomedical Analysis, 2019, 165, 381-385.	2.8	103
2	Determination of clopidogrel metabolite (SR26334) in human plasma by LC–MS. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 533-539.	2.8	61
3	Quantitative evaluation of the matrix effect in bioanalytical methods based on LC–MS: A comparison of two approaches. Journal of Pharmaceutical and Biomedical Analysis, 2018, 155, 314-319.	2.8	35
4	Simplified LC–MS/MS method enabling the determination of azithromycin in human plasma after a low 100 mg dose administration. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 184-189.	2.8	23
5	Cloud-point extraction is compatible with liquid chromatography coupled to electrospray ionization mass spectrometry for the determination of bisoprolol in human plasma. Journal of Chromatography A, 2015, 1423, 39-46.	3.7	21
6	An overview of chromatographic methods coupled with mass spectrometric detection for determination of angiotensin-converting enzyme inhibitors in biological material. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 356-367.	2.8	18
7	Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry. Journal of Separation Science, 2014, 37, 2652-2658.	2.5	15
8	Low-oxidation-potential thiophene-carbazole monomers for electro-oxidative molecular imprinting: Selective chemosensing of aripiprazole. Biosensors and Bioelectronics, 2020, 169, 112589.	10.1	15
9	Matrix effect screening for cloud-point extraction combined with liquid chromatography coupled to mass spectrometry: Bioanalysis of pharmaceuticals. Journal of Chromatography A, 2019, 1591, 44-54.	3.7	14
10	Comprehensive graphical presentation of data from incurred sample reanalysis. Bioanalysis, 2017, 9, 947-956.	1.5	13
11	Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?. AAPS Journal, 2019, 21, 28.	4.4	12
12	Application of confidence intervals to bioanalytical method validation-drug stability in biological matrix testing. Acta Poloniae Pharmaceutica, 2008, 65, 743-7.	0.1	9
13	Is a deuterated internal standard appropriate for the reliable determination of olmesartan in human plasma?. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1040, 53-59.	2.3	8
14	Incurred sample reanalysis: adjusted procedure for sample size calculation. Bioanalysis, 2017, 9, 1719-1726.	1.5	7
15	Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1905-1910.	2.3	6
16	Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma. Acta Poloniae Pharmaceutica, 2014, 71, 1029-36.	0.1	6
17	Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers. Kardiologia Polska, 2017, 75, 48-54.	0.6	5
18	Combined Protein and Alkaloid Research of Chelidonium majus Latex Reveals CmMLP1 Accompanied by Alkaloids with Cytotoxic Potential to Human Cervical Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 11838.	4.1	5

Piotr JÃ³zef Rudzki

#	Article	IF	CITATIONS
19	Determination of duloxetine in human plasma with proven lack of influence of the major metabolite 4-hydroxyduloxetine. Clinical Biochemistry, 2014, 47, 1313-1315.	1.9	4
20	Extended 3D and 4D cumulative plots for evaluation of unmatched incurred sample reanalysis. Bioanalysis, 2018, 10, 153-162.	1.5	4
21	Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 909-19.	0.6	4
22	HPLC-UV ASSAY OF IMATINIB IN HUMAN PLASMA OPTIMIZED FOR BIOEQUIVALENCE STUDIES. Acta Poloniae Pharmaceutica, 2016, 73, 1495-1503.	0.1	4
23	10th Anniversary of a Two-Stage Design in Bioequivalence. Why Has it Still Not Been Implemented?. Pharmaceutical Research, 2020, 37, 140.	3.5	3
24	Validated LC-MS method for determination of tamsulosin in human plasma and its application to pharmacokinetic study. Acta Poloniae Pharmaceutica, 2006, 63, 417-9.	0.1	3
25	Bioequivalence study of 500 mg cefuroxime axetil film-coated tablets in healthy volunteers. Acta Poloniae Pharmaceutica, 2012, 69, 1356-63.	0.1	3
26	Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacological Reports, 2021, 73, 604-614.	3.3	2
27	Validated HPLC method for determination of cefuroxime in human plasma. Acta Poloniae Pharmaceutica, 2010, 67, 677-81.	0.1	2
28	ENVIRONMENTALLY FRIENDLY LC/MS DETERMINATION OF EPLERENONE IN HUMAN PLASMA. Acta Poloniae Pharmaceutica, 2016, 73, 1487-1493.	0.1	2
29	Bioequivalence Study of 8 mg Ondansetron Film-coated Tablets in Healthy Caucasian Volunteers. Drug Research, 2014, 64, 220-224.	1.7	1
30	Visualizing bioanalytical methods – a near or distant future?. Bioanalysis, 2020, 12, 427-429.	1.5	1
31	ORBIS (Open Research Biopharmaceutical Internships Support) – building bridges between academia and pharmaceutical industry to improve drug development. Journal of Medical Science, 2020, 89, e419.	0.7	1
32	Replicates Number for Drug Stability Testing during Bioanalytical Method Validation—An Experimental and Retrospective Approach. Molecules, 2022, 27, 457.	3.8	1